Our portfolio of autologous and allogeneic cell therapies are built on platforms that combine T cells with other immuno-oncology approaches. Our lead candidate comprises autologous CD30 CAR-T cell therapy targeting classical Hodgkin lymphoma (cHL) and CD30+ non-Hodgkin lymphomas.
TT11x and TT16 are Investigator-initiated trials funded by Tessa. All of Tessa’s programs are not yet being offered for sale and are currently undergoing investigation. Accordingly, Tessa makes no claim as to their safety and effectiveness for the purposes for which they are under investigation.
CD30-Directed Genetically Modified Autologous T cells (CD30.CAR-T) in Adult and Pediatric Patients with Relapsed or Refractory CD30 Positive Classical Hodgkin Lymphoma
Tessa is initiating a Phase II clinical study to investigate an autologous CD30.CAR-T cell therapy program targeting relapsed or refractory classical Hodgkin Lymphoma. CD30-targeting CAR enables the recognition and elimination of CD30-positive lymphoma cells.
This therapy is developed based on encouraging clinical data from two independent CD30.CAR-T Phase I/II studies conducted by Baylor College of Medicine (Trial Number: NCT02917083), and the University of North Carolina (Trial Number: NCT02690545), for patients with relapsed or refractory CD30-positive Hodgkin Lymphoma. CD30.CAR-T were administered after lymphodepletion with either bendamustine alone, bendamustine and fludarabine, or cyclophosphamide and fludarabine.
Allogeneic CD30-Chimeric Antigen Receptor (CAR) Epstein-Barr Virus-Specific T cells (EBVSTs) for CD30 Positive Lymphomas
Tessa is developing a next-generation, allogeneic VST therapy targeting CD30-Positive Lymphomas. EBVST cell lines derived from healthy donors are modified with a CD30 Chimeric Antigen Receptor (CAR) and matched to suitable patients to target CD30+ cancer cells within their bodies.
This therapy is developed based on an ongoing Phase 1 clinical study (Trial Number: NCT02287311) conducted by Baylor College of Medicine, which investigates the feasibility and safety of allogeneic EBVSTs in EBV-associated lymphomas.
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL) (MABEL)
Indication: EBV-associated lymphomas and PTLD
Trial Number: NCT02287311
Most Closely Matched 3rd Party Rapidly Generated LMP, BARF1 And EBNA1 Specific CTL, EBV-Positive Lymphoma (MABEL)
Texas, United States
Allogeneic CD30.CAR-EBVSTs in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Indication: Extranodal NK/T-Cell Lymphoma (Nasal Type), Classical Hodgkin Lymphoma and PTLD
Trial Number: NCT04288726
A Phase 1 Study Evaluating the Safety and Activity of Allogeneic CD30 Chimeric Antigen Receptor Epstein-Barr Virus-Specific T Lymphocytes (CD30.CAR-EBVSTs) in Patients With Relapsed or Refractory CD30-Positive Lymphomas
Texas, United States
HER2 CAR-Ts + Oncolytic & Helper-Dependent Adenovirus for HER2-positive solid tumors
Human Epidermal Growth Factor Receptor 2 (HER2) is over expressed in multiple solid tumors, including breast cancer, bladder cancer, lung, colorectal, gastric carcinoma, and head and neck. The overexpression of HER2 is an indicator of poor prognosis, increased recurrence and decreased overall survival (OS). The administration of our therapy is a two-step process: the adenoviruses are administered locally into the tumor, followed by infusion of HER2 CAR-Ts.
Selectively replicates and kills tumor cells to promote inflammation
Expresses IL-12 and checkpoint inhibitor anti-PD-L1. Modulates the tumor microenvironment to promote a strong anti-tumor response.
HER2-specific CAR-T Cell
Targets and specifically kills HER2 expressing tumor cells
Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors (VISTA)
Indication: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland, Lung Cancer, Breast Cancer, Gastric Cancer, Esophageal Cancer, Colorectal Cancer, Pancreatic Adenocarcinoma, Solid Tumor
Trial Number: NCT03740256
A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors
Texas, United States